{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:35:33Z","timestamp":1756895733183},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T00:00:00Z","timestamp":1382572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40272-013-0053-1","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T14:34:21Z","timestamp":1382538861000},"page":"515-531","source":"Crossref","is-referenced-by-count":15,"title":["Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis"],"prefix":"10.1007","volume":"15","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,24]]},"reference":[{"issue":"9563","key":"53_CR1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"issue":"1","key":"53_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ncprheum0084","volume":"2","author":"P Woo","year":"2006","unstructured":"Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2(1):28\u201334.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"53_CR3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/rheumatology\/41.12.1428","volume":"41","author":"JC Packham","year":"2002","unstructured":"Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41:1428\u201335.","journal-title":"Rheumatology (Oxford)"},{"key":"53_CR4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.10863","volume":"48","author":"HE Foster","year":"2003","unstructured":"Foster HE, Marshall N, Myers A, et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48:767\u201375.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"53_CR5","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"key":"53_CR6","doi-asserted-by":"crossref","unstructured":"Gurion R, Lehman TJA, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam. 2012. doi: 10.1155\/2012\/271569 . http:\/\/www.hindawi.com\/journals\/iji\/2012\/271569\/cta\/ . Accessed 2 Sep 2013.","DOI":"10.1155\/2012\/271569"},{"issue":"5","key":"53_CR7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/acr.21889","volume":"65","author":"Y Kimura","year":"2013","unstructured":"Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(5):745\u201352.","journal-title":"Arthritis Care Res"},{"key":"53_CR8","first-page":"106","volume":"27","author":"C Hoffart","year":"2010","unstructured":"Hoffart C, Sherry DD. More aggressive treatment for juvenile idiopathic arthritis. J Musculoskel Med. 2010;27:106\u20138.","journal-title":"J Musculoskel Med"},{"issue":"3","key":"53_CR9","first-page":"191","volume":"11","author":"PPW Lee","year":"2006","unstructured":"Lee PPW, Lee TL, Wong WHS, et al. The use of methotrexate in juvenile idiopathic arthritis: a single center experience. HK J Pediatr. 2006;11(3):191\u20138.","journal-title":"HK J Pediatr"},{"key":"53_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1542\/peds.109.1.109","volume":"109","author":"NT Ilowite","year":"2002","unstructured":"Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics. 2002;109:109\u201315.","journal-title":"Pediatrics"},{"key":"53_CR11","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.294.13.1671","volume":"294","author":"PJ Hashkes","year":"2005","unstructured":"Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294:1671\u201384.","journal-title":"JAMA"},{"key":"53_CR12","first-page":"71","volume":"4","author":"M Murakami","year":"2012","unstructured":"Murakami M, Tomiita M, Nishimoto N. Tocilizumab in the treatment of systemic juvenile idiopathic arthritis. Open Access Rheumatol Res Rev. 2012;4:71\u20139.","journal-title":"Open Access Rheumatol Res Rev"},{"issue":"2","key":"53_CR13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/ecp.13.1","volume":"6","author":"X Zhang","year":"2013","unstructured":"Zhang X, Morcos PN, Saito T, et al. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2013;6(2):123\u201337.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"53_CR14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.bor.0000265447.48722.04","volume":"19","author":"MAA Siddiqui","year":"2007","unstructured":"Siddiqui MAA. The efficacy and tolerability of newer biologics in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19(3):308\u201313.","journal-title":"Curr Opin Rheumatol"},{"key":"53_CR15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-013-0018-2","volume":"73","author":"MY Md Yusof","year":"2013","unstructured":"Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs. 2013;73:341\u201356.","journal-title":"Drugs"},{"issue":"3","key":"53_CR16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.20946","volume":"52","author":"F Benedetti De","year":"2005","unstructured":"De Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum. 2005;52(3):687\u201393.","journal-title":"Arthritis Rheum"},{"key":"53_CR17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"53_CR18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"key":"53_CR19","unstructured":"Immunex Corporation. Enbrel\u00ae (etanercept) solution for subcutaneous use. US prescribing information. 2013. http:\/\/pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf . Accessed 2 Sep 2013."},{"key":"53_CR20","unstructured":"AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use. US prescribing information. 2013. http:\/\/www.rxabbvie.com\/pdf\/humira.pdf . Accessed 4 Sep 2013."},{"key":"53_CR21","unstructured":"Pfizer Limited. Enbrel 25\u00a0mg powder and solvent for solution for injection. EU summary of product characteristics. 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf . Accessed 2 Sep 2013."},{"key":"53_CR22","unstructured":"AbbVie Ltd. Humira 40\u00a0mg\/0.8\u00a0ml solution for injection for paediatric use. EU summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf . Accessed 4 Sep 2013."},{"issue":"9","key":"53_CR23","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106.","journal-title":"Arthritis Rheum"},{"issue":"9636","key":"53_CR24","first-page":"383","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. N Engl J Med. 2008;372(9636):383\u201391.","journal-title":"N Engl J Med"},{"key":"53_CR25","unstructured":"Bristol-Myers Squibb Company. ORENCIA (abatacept) for injection for intravenous use; injection, for subcutaneous use. US prescribing information. 2013. http:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf . Accessed 4 Sep 2013."},{"key":"53_CR26","unstructured":"Bristol-Myers Squibb Pharma EEIG. ORENCIA 250\u00a0mg powder for concentrate for solution for infusion. EU summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000701\/WC500048935.pdf . Accessed 4 Sep 2013."},{"issue":"25","key":"53_CR27","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"key":"53_CR28","unstructured":"Novartis Pharmaceuticals Corporation. ILARIS (canakinumab) injection for subcutaneous use. US prescribing information. 2013. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/ilaris.pdf . Accessed 4 Sep 2013."},{"key":"53_CR29","unstructured":"Novartis Europharm Limited. ILARIS 150\u00a0mg powder for solution for injection. EU summary of product characteristics. 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001109\/WC500031680.pdf . Accessed 14 Oct 2013."},{"issue":"5","key":"53_CR30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"53_CR31","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum. 2013;65(9):2486\u201396.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"53_CR32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","volume":"69","author":"V Oldfield","year":"2009","unstructured":"Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69(5):609\u201332.","journal-title":"Drugs"},{"issue":"6","key":"53_CR33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1759720X12455960","volume":"4","author":"S Yokota","year":"2012","unstructured":"Yokota S, Tanaka T, Kishomoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387\u201397.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"53_CR34","unstructured":"Genentech Inc. ACTEMRA\u00ae (tocilizumab) injection, for intravenous infusion. US prescribing information. 2013. http:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf . Accessed 2 Sep 2013."},{"key":"53_CR35","unstructured":"Roche Pharma AG. RoActemra 20\u00a0mg\/mL concentrate for solution for infusion. EU summary of product characteristics 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000955\/WC500054890.pdf . Accessed 2 Sep 2013."},{"issue":"5","key":"53_CR36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/ecp.11.33","volume":"4","author":"X Zhang","year":"2011","unstructured":"Zhang X, Peck R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev Clin Pharmacol. 2011;4(5):539\u201358.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"53_CR37","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/clpt.2012.258","volume":"93","author":"X Zhang","year":"2013","unstructured":"Zhang X, Hsu J, Brunner H, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in polyarticular-course juvenile idiopathic arthritis (PCJIA) [abstract no. PIII-2]. Clin Pharmacol Ther. 2013;93:S88\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"53_CR38","first-page":"415","volume":"29","author":"F Benedetti De","year":"2011","unstructured":"De Benedetti F, Ruperto N, Brunner H, et al. Tocilizumab improves systemic and laboratory features of systemic juvenile idiopathic arthritis: 12-week data from the phase 3 TENDER trial [abstract no. P138]. Clin Exp Rheumatol. 2011;29(2):415.","journal-title":"Clin Exp Rheumatol"},{"key":"53_CR39","doi-asserted-by":"crossref","first-page":"S682","DOI":"10.1002\/art.34426","volume":"64","author":"H Brunner","year":"2012","unstructured":"Brunner H, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial [abstract no. 1597]. Arthritis Rheum. 2012;64:S682.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"53_CR40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","volume":"22","author":"T Kishimoto","year":"2010","unstructured":"Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22(5):347\u201352.","journal-title":"Int Immunol"},{"issue":"4","key":"53_CR41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H, et al. IL-6\/IL-6R receptor system and its role in physiological and pathophysiological conditions. Clin Sci. 2012;122(4):143\u201359.","journal-title":"Clin Sci"},{"key":"53_CR42","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S. IL-6 trans-signalling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8:1237\u201347.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"53_CR43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.11.5.613","volume":"11","author":"S Rose-John","year":"2007","unstructured":"Rose-John S, Waetzig GH, Scheller J, et al. The IL-6\/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 2007;11(5):613\u201324.","journal-title":"Expert Opin Ther Targets"},{"key":"53_CR44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","volume":"80","author":"S Rose-John","year":"2006","unstructured":"Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leuk Biol. 2006;80:227\u201336.","journal-title":"J Leuk Biol"},{"issue":"9","key":"53_CR45","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","volume":"121","author":"SA Jones","year":"2011","unstructured":"Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6\/gp-130 signalling. J Clin Invest. 2011;121(9):3375\u201383.","journal-title":"J Clin Invest"},{"key":"53_CR46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"J-M Dayer","year":"2010","unstructured":"Dayer J-M, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology. 2010;49:15\u201324.","journal-title":"Rheumatology"},{"issue":"12","key":"53_CR47","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731\u201340.","journal-title":"Int Immunopharmacol"},{"key":"53_CR48","unstructured":"Roy P. Clinical pharmacology review. Actemra. http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM259750.pdf . Accessed 2 Sep 2013."},{"key":"53_CR49","unstructured":"Zhang X, Morcos PN, De Benedetti F, et al. Pharmacokinetics and pharmacodynamics of tocilizumab in systemic juvenile idiopathic arthritis [abstract no. 255E]. Pharmacotherapy. 2011;31(10):381e-2e."},{"issue":"Suppl. 1","key":"53_CR50","first-page":"S36","volume":"89","author":"X Zhang","year":"2011","unstructured":"Zhang X, Morcos PN, De Benedetti F, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) [abstract no. OII-A-2]. Clin Pharmacol Ther. 2011;89(Suppl. 1):S36.","journal-title":"Clin Pharmacol Ther"},{"key":"53_CR51","unstructured":"Zhang X, Morcos PN, De Benedetti F, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) [abstract no. FRI0200]. Ann Rheum Dis. 2011;70."},{"issue":"6","key":"53_CR52","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1345\/aph.1Q756","volume":"46","author":"K Decelle","year":"2012","unstructured":"Decelle K, Horton ER. Tocilizumab for the treatment of juvenile idiopathic arthritis. Ann Pharmacother. 2012;46(6):822\u20139.","journal-title":"Ann Pharmacother"},{"key":"53_CR53","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Assessment report: RoActemra. International non-proprietary name: tocilizumab. Procedure no. EMEA\/H\/C\/000955\/II\/0026. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000955\/WC500145204.pdf . Accessed 2 Sep 2013."},{"issue":"25","key":"53_CR54","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"2","key":"53_CR55","first-page":"370","volume":"29","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, De Benedetti F, Brunner H, et al. Tocilizumab is efficacious in patients with systemic juvenile idiopathic arthritis (sJIA) across baseline disease characteristics and prior\/baseline treatments: 12-week data from the phase 3 TENDER trial [abstract no. O13]. Clin Exp Rheumatol. 2011;29(2):370\u20131.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 1","key":"53_CR56","first-page":"A58","volume":"10","author":"F Benedetti De","year":"2011","unstructured":"De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data [abstract]. Pediatr Rheum. 2011;10(Suppl. 1):A58.","journal-title":"Pediatr Rheum"},{"issue":"Suppl. 3","key":"53_CR57","first-page":"iii76","volume":"51","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner H, Allen R, et al. The efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis: 52-week data from a phase 3 clinical trial [abstract no. 68]. Rheumatology. 2012;51(Suppl. 3):iii76.","journal-title":"Rheumatology"},{"key":"53_CR58","unstructured":"De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis: 2-year data from a phase III clinical trial [abstract no. L12]. Arthritis Rheum. 2011;63(12):4047. Slides accompanying this abstract are available online at: https:\/\/acr.confex.com\/acr\/2011\/recordingredirect.cgi\/id\/806 ."},{"key":"53_CR59","unstructured":"Hoffman-La Roche. A study of RoActemra\/Actemra (tocilizumab) in patients with active systemic juvenile idiopathic arthritis [ClinicalTrials.gov identifier NCT00642460]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00642460 . Accessed 2 Sep 2013."},{"key":"53_CR60","unstructured":"Hoffman-La Roche. Roche trials database. Clinical trial result information. Protocol number: WA18221. 2011. http:\/\/www.roche-trials.com\/studyResultGet.action?studyResultNumber=WA18221 . Accessed 2 Sep 2013."},{"key":"53_CR61","unstructured":"Hoffman-La Roche. A study of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis [ClinicalTrials.gov identifier NCT00988221]. US National Institutes of Health, ClinicalTrials.gov [online]. 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00988221 . Accessed 2 Sep 2013."},{"key":"53_CR62","unstructured":"Hoffman-La Roche. Roche trials database. Clinical trial result information. Protocol number: WA19977. 2012. http:\/\/www.roche-trials.com\/studyResultGet.action?studyResultNumber=WA19977 . Accessed 2 Sep 2013."},{"key":"53_CR63","unstructured":"Chugai Pharmaceutical. Study of MRA for systemic juvenile idiopathic arthritis (sJIA) [ClinicalTrials.gov identifier NCT00144599]. US National Institutes of Health, ClinicalTrials.gov [online]. 2008. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00144599 . Accessed 2 Sep 2013."},{"key":"53_CR64","unstructured":"Chugai Pharmaceutical. Long-term treatment study of MRA for systemic juvenile idiopathic arthritis (sJIA) [ClinicalTrials.gov identifier NCT00144612]. US National Institutes of Health, ClinicalTrials.gov [online]. 2009. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00144612 . Accessed 2 Sep 2013."},{"issue":"9617","key":"53_CR65","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998\u20131006.","journal-title":"Lancet"},{"issue":"4","key":"53_CR66","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2012-202310","volume":"72","author":"S Yokota","year":"2013","unstructured":"Yokota S, Imagawa T, Mori M, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2013;72(4):627\u20138.","journal-title":"Ann Rheum Dis"},{"key":"53_CR67","unstructured":"Chugai Pharmaceutical. Study of MRA for polyarticular juvenile idiopathic arthritis (pJIA) [ClinicalTrials.gov identifier NCT00144664]. US National Institutes of Health, ClinicalTrials.gov [online]. 2008. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00144664 . Accessed 2 Sep 2013."},{"key":"53_CR68","unstructured":"Chugai Pharmaceutical. Long-term treatment study of MRA for polyarticular juvenile idiopathic arthritis (pJIA) [ClinicalTrials.gov identifier NCT00144625]. US National Institutes of Health, ClinicalTrials.gov [online]. 2009. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00144625 . Accessed 2 Sep 2013."},{"issue":"1","key":"53_CR69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10165-011-0481-0","volume":"22","author":"T Imagawa","year":"2012","unstructured":"Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22(1):109\u201315.","journal-title":"Mod Rheumatol"},{"key":"53_CR70","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Assessment report for RoActemra. International non-proprietary name: tocilizumab. Procedure no. type II variation EMEA\/H\/C\/955\/II\/15. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000955\/WC500111086.pdf . Accessed 17 Sep 2013."},{"key":"53_CR71","doi-asserted-by":"crossref","unstructured":"De Benedetti F, Ruperto N, Brunner HI, et al. Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the TENDER study [abstract no. 2139]. 20th Congress of the European Paediatric Rheumatology Society; Ljubljana; 2013.","DOI":"10.1186\/1546-0096-11-S2-P151"},{"key":"53_CR72","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1002\/art.33369","volume":"64","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Ruperto N, Espada G, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial [abstract no. 760]. Arthritis Rheum. 2012;64:S327.","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"53_CR73","doi-asserted-by":"crossref","first-page":"P130","DOI":"10.1186\/1546-0096-9-S1-P130","volume":"9","author":"T Miyamae","year":"2011","unstructured":"Miyamae T, Nozawa T, Kikuchi M, et al. Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis [abstract]. Pediatr Rheumatol. 2011;9(Suppl. 1):P130.","journal-title":"Pediatr Rheumatol"},{"issue":"9","key":"53_CR74","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/ard.2010.145359","volume":"70","author":"Y Inaba","year":"2011","unstructured":"Inaba Y, Ozawa R, Imagawa T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis. 2011;70(9):1693\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"53_CR75","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10165-012-0595-z","volume":"22","author":"T Shinoki","year":"2012","unstructured":"Shinoki T, Hara R, Kaneko U, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 2012;22(6):871\u20136.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"53_CR76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10165-011-0464-1","volume":"21","author":"S Yokota","year":"2011","unstructured":"Yokota S, Imagawa T, Takei S, et al. Guidance on using tocilizumab for juvenile idiopathic arthritis. Mod Rheumatol. 2011;21(6):563\u201371.","journal-title":"Mod Rheumatol"},{"key":"53_CR77","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-4614-4726-9_12","volume":"764","author":"D Isaacs","year":"2013","unstructured":"Isaacs D. Infectious risks associated with biologics. Adv Exp Med Biol. 2013;764:151\u20138.","journal-title":"Adv Exp Med Biol"},{"key":"53_CR78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157339711794474620","volume":"7","author":"F Keyer De","year":"2011","unstructured":"De Keyer F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7:77\u201387.","journal-title":"Curr Rheumatol Rev"},{"issue":"2","key":"53_CR79","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","volume":"58","author":"M Shimizu","year":"2012","unstructured":"Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287\u201394.","journal-title":"Cytokine"},{"issue":"13","key":"53_CR80","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMc1301017","volume":"368","author":"F Benedetti De","year":"2013","unstructured":"De Benedetti F. Comment on: Tocilizumab for systemic juvenile idiopathic arthritis. N Engl J Med. 2013;368(13):1256\u20137.","journal-title":"N Engl J Med"},{"key":"53_CR81","unstructured":"Hoffman-La Roche. A study to compare subcutaneous versus intravenous administration of RoActemra\/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis [ClinicalTrials.gov identifier NCT01194414]. US National Institutes of Health, ClinicalTrials.gov [online]. 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01194414 . Accessed 2 Sep 2013."},{"issue":"8","key":"53_CR82","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5414\/CP201904","volume":"51","author":"X Zhang","year":"2013","unstructured":"Zhang X, Chen YC, Fettner S, et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2013;51(8):620\u201330.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"53_CR83","unstructured":"Chugai Pharmaceutical Co. Ltd. Launch of subcutaneous injection formulation, Actemra\u00ae, for a treatment of rheumatoid arthritis. The first anti-IL-6 receptor antibody in subcutaneous market [media release]. 24 May 2013. www.roche.com\/inv-update-2013-05-24-annex.pdf ."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0053-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-013-0053-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0053-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T06:12:01Z","timestamp":1564553521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-013-0053-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,24]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["53"],"URL":"https:\/\/doi.org\/10.1007\/s40272-013-0053-1","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,24]]}}}